Summary Box: Vertex's hep C drug Incivek approved

Mon, 05/23/2011 - 9:17am
The Associated Press

CLEARANCE: Vertex Pharmaceuticals Inc.'s hepatitis C drug Incivek received marketing approval Monday, about a week after the Food and Drug Administration approved a competing pill.

NEW ENTRY: Incivek and Merck and Co.'s Victrelis are both are taken three times a day as part of a drug cocktail, and they are significantly more effective than older drugs at curing hepatitis C, a chronic disease of the liver. Standard therapies cure less than half of all patients.

PRICE: Vertex says a 12-week course of Incivek treatment will cost $49,200, although it is offering financial support for some patients.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.